Lipocine’s LPCN 2101 Accepted for AES Presentation

An update from Lipocine ( (LPCN) ) is now available.

On August 26, 2025, Lipocine announced that two abstracts related to LPCN 2101, a drug candidate for epilepsy treatment, were accepted for presentation at the 2025 American Epilepsy Society annual meeting in December. This acceptance highlights Lipocine’s ongoing efforts to advance its epilepsy treatment pipeline, potentially enhancing its positioning in the biopharmaceutical industry and offering new opportunities for stakeholders.

The most recent analyst rating on (LPCN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Spark’s Take on LPCN Stock

According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.

Lipocine’s overall stock score reflects a mix of financial recovery and strategic progress against a backdrop of technical and valuation challenges. The company’s strong balance sheet and recent corporate developments provide a foundation for future growth, but consistent profitability and improved market sentiment are needed to enhance the stock’s attractiveness.

To see Spark’s full report on LPCN stock, click here.

More about Lipocine

Lipocine Inc. is a biopharmaceutical company that utilizes its proprietary technology platform to develop innovative products with effective oral delivery. The company focuses on creating drug candidates that offer differentiated, patient-friendly oral delivery options targeting large addressable markets with significant unmet medical needs. Lipocine’s development portfolio includes treatments for conditions such as postpartum depression, epilepsy, essential tremor, obesity management, and liver cirrhosis.

Average Trading Volume: 39,855

Technical Sentiment Signal: Sell

Current Market Cap: $16.37M

See more insights into LPCN stock on TipRanks’ Stock Analysis page.